Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00391872 · ClinicalTrials.gov registry record · Phase 3

A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome

A Phase 3 study of Acute Coronary Syndrome, sponsored by AstraZeneca.

Compiled by PlainTrial · August 8, 2026

Completed
Registry status: Phase 3
Development phase: 18,624
Enrollment target: 20
Study locations

NCT00391872: Completed Phase 3 study of Acute Coronary Syndrome, sponsored by AstraZeneca.

NCT00391872 is a Phase 3 study of Acute Coronary Syndrome that has completed, run by AstraZeneca. The registered enrollment target is 18,624 participants, above the 2,256-participant average among 40 other Acute Coronary Syndrome trials with a reported enrollment target (726% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00391872, a Phase 3 study of Acute Coronary Syndrome, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status: Phase 3
Development phase: 18,624 participants
Enrollment target: 20
Study locations

Study Summary

Ticagrelor is a new, reversible binding, anti-platelet medication. Anti-platelet medications work to prevent the formation of blood clots. Ticagrelor is being developed as a treatment for patients with acute coronary syndrome (ACS). ACS is a term that is used to describe both heart attacks in progress or the imminent threat of a heart attack. ACS is usually caused by the formation of a blood clot in an artery that partially or totally blocks the blood supply to a portion of the heart muscle. Ticagrelor will be compared with clopidogrel to determine which drug, when either is used in conjunction with aspirin, is better at reducing deaths from vascular causes, future heart attacks and/or strokes in patients with ACS.

Primary Outcome

Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. Intention To Treat (ITT) analysis of whole population. Events were adjudicated by an endpoint committee.

Conditions Studied

Acute Coronary Syndrome

Interventions

DRUG Clopidogrel
DRUG Ticagrelor

Study Locations (20)

California

Research Site - Bakersfield
Research Site - Beverly Hills
Research Site - Burbank
Research Site - Healdsburg
Research Site - Los Angeles
Research Site - Roseville
Research Site - Sacramento
Research Site - San Diego
Research Site - Torrance

Alabama

Research Site - Birmingham
Research Site - Huntsville
Research Site - Mobile

Connecticut

Research Site - Danbury
Research Site - Hartford

Florida

Research Site - Atlantis
Research Site - Daytona Beach

Arizona

Research Site - Tucson

Colorado

Research Site - Fort Collins

Delaware

Research Site - Newark

District of Columbia

Research Site - Washington D.C.

Trial Details

Field	Value
Enrollment Target	18,624 participants
Start Date	2006-10
Est. Completion	2009-03
Phase	Phase 3

AstraZeneca

1,285 total trials

What the finished NCT00391872 record still lists

NCT00391872 is an interventional study that assigns participants to a tested intervention. Its 18,624 participants enrollment target places it among the larger protocols in the corpus, above the 2,256-participant average among 40 other Acute Coronary Syndrome trials with a reported enrollment target (726% higher).

The record links to 1 condition, with Acute Coronary Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Clopidogrel is the first listed.

NCT00391872 names 20 study sites across 8 states, led by California, Alabama, Connecticut.

Frequently Asked Questions

What is clinical trial NCT00391872 about?

NCT00391872 is a clinical study titled "A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome". Ticagrelor is a new, reversible binding, anti-platelet medication. Anti-platelet medications work to prevent the formation of blood clots. Ticagrelor is being developed as a treatment for patients with acute coronary syndrome (ACS). ACS is a term that is used to describe both heart attacks in progre...

What is the current status of trial NCT00391872?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 18,624 participants. The study started on 2006-10. Estimated completion is 2009-03.

What conditions does trial NCT00391872 study?

This clinical trial studies the following conditions: Acute Coronary Syndrome.

What interventions are being tested in trial NCT00391872?

The interventions under investigation include: Clopidogrel (DRUG), Ticagrelor (DRUG).

Who is sponsoring clinical trial NCT00391872?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00391872 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Coronary Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00391872's enrollment target sits among peer trials

18,624 1st of 40 higher than 40 of 40 other Acute Coronary Syndrome trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Acute Coronary Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

NCT04372875 · 18,500 participants · NA
Health Information Technology to Reduce Disparities in Adolescent Health Outcomes: A Pragmatic Trial
NCT04110522 · 18,000 participants · NA
Psoriatic Arthritis D2P Screening
NCT05513833 · 18,000 participants · NA
School Screening and Telemedicine Specialty Referral to Address Childhood Hearing Loss in Rural Kentucky
NCT06802224 · 18,000 participants · Phase 4
The Choice of Vasopressor to Prevent Postoperative Acute Kidney Injury After Major Non-Cardiac Surgery

Similar registry start date

NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00391872, the US trial registry maintained by the National Library of Medicine. NCT00391872 (large enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.